Trastuzumab: A picky partner? Journal Article

  


Authors: Mcarthur, H. L.; Hudis, C. A.
Article Title: Trastuzumab: A picky partner?
Abstract: Preclinical and clinical models of HER2-positive breast cancer show that human epidermal growth factor receptor 2 (HER2)-targeted therapy with trastuzumab adds significant benefits and modest risks to conventional cytotoxic therapies. Building on this advance will likely depend on elucidation of relevant signaling pathways and mechanisms of action for effective HER2-targeted therapies. © 2009 American Association for Cancer Research.
Keywords: signal transduction; cancer chemotherapy; cytotoxic agent; nonhuman; risk benefit analysis; note; drug targeting; capecitabine; paclitaxel; animals; cell survival; metastasis; progression free survival; breast cancer; cell growth; epidermal growth factor receptor 2; relapse; cyclophosphamide; cell differentiation; receptor, epidermal growth factor; cytotoxicity; breast neoplasms; cancer hormone therapy; drug delivery systems; antibodies, monoclonal; drug mechanism; trastuzumab; lapatinib; hemopoietic growth factor
Journal Title: Clinical Cancer Research
Volume: 15
Issue: 20
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2009-10-15
Start Page: 6311
End Page: 6313
Language: English
DOI: 10.1158/1078-0432.ccr-09-1917
PUBMED: 19825955
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-70350223973&partnerID=40&md5=eb0ee940b4782d97f45e50787a7ad1de
Notes: --- - "Cited By (since 1996): 2" - "Export Date: 30 November 2010" - "CODEN: CCREF" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Clifford Hudis
    905 Hudis
  2. Heather Lynn Mcarthur
    82 Mcarthur
Related MSK Work